KWF
Validation of Biomarkers
12:00 noon; Full proposal deadline 23 February 2027, 12:00 noon
Last updated:
KWF's Validation of Biomarkers call funds the clinical translation of established oncology biomarkers (TRL 5-6) into daily practice, offering €800,000-€2 million over 2-5 years. Applicants must assemble a multidisciplinary consortium of at least four parties, including a biostatistician and health technology assessment (HTA) expert, with mandatory patient involvement; Dutch-based institutions lead the application. This is a competitive, two-stage call emphasising de-risked translational research with immediate clinical utility.
Details
| Funder | KWF |
| Budget | €0.8M–€2M |
| Deadline | 20 October 2026 |
| Duration | 2-5 years |
| Consortium | Required — multidisciplinary consortium of minimum 4 participating parties (may include private partners) |
| Application | 2-stage: pre-proposal (deadline 20 October 2026) → full proposal (deadline 23 February 2027) → interviews (May 2027) → funding decision (June 2027) |
| TRL | 5-6 |
| Frequency | Annual |
| Eligible countries | NL |
Eligibility & scope
Funds clinical validation (TRL5/6) of already-known cancer biomarkers via multidisciplinary consortia including biostatistician and HTA-expert; mandatory HTA component, patient involvement, and development plan for implementation. AI-component projects must involve the AI4Health consortium as partner or advisor.
Who Should Apply
- •Multidisciplinary consortia of at least 4 parties (academic, clinical, industry, or diagnostic partner mix)
- •Dutch-based lead institutions with biostatistician and HTA expertise on the team
- •Researchers with known oncology biomarkers at technology readiness level 5-6 ready for clinical validation
- •Projects with structured patient involvement and a clear pathway to routine clinical implementation
- •AI-focused projects must commit to engagement with the AI4HEALTH consortium
Key Dates
- •Pre-proposal deadline: 20 October 2026 at 12:00 noon; full proposal deadline: 23 February 2027 at 12:00 noon
- •Two-stage review followed by interviews in May 2027
- •2- to 5-year project duration
Tips for Applicants
- ✓Assemble your consortium early and ensure explicit letters of commitment from each party; KWF screens for genuine co-investment and clear role delineation.
- ✓The HTA component is non-negotiable, include a health economist or HTA specialist in your core team, not as an afterthought, to show you understand cost-effectiveness alongside clinical validity.
- ✓Patient involvement must be active and described in the pre-proposal; token representation will weaken your score. Specify how patients shape the research question and co-design validation endpoints.
Frequently Asked Questions
What is the budget range for the KWF Validation of Biomarkers call?
€800,000 to €2 million per project over a 2- to 5-year period.
Who must be part of the consortium?
A minimum of four participating parties, including a biostatistician and a health technology assessment expert; private partners are eligible. Patient representatives must be actively involved.
What is the technology readiness level (TRL) requirement?
Projects must target biomarkers at TRL 5-6, meaning the biomarker is known and ready for clinical validation, not discovery-stage research.
Are Dutch institutions required?
Yes, the eligible country is the Netherlands and Dutch-based institutions are expected to lead applications.
When are the application deadlines?
Pre-proposal deadline is 20 October 2026 at noon; full proposal deadline is 23 February 2027 at noon. Shortlisted candidates are interviewed in May 2027.
Related on Grantsby
- KWF writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
Similar grants
Implementation of Biomarkers
KWFDeadline: 20 Oct 2026€1M–€4MVirtual Human Twin (VHT) Models for Cancer Research (HORIZON-MISS-2026-02-CANCER-01)
European CommissionDeadline: 15 Sept 2026€8M–€9M per grant (total budget €35M)Advanced multiscale Virtual Human Twins for cancer onset and progression
European CommissionNext steps
CancerfondenDeadline: 15 Dec 2026Microbiome tools for cancer prevention and early detection
European Commission
Browse Related
Could Validation of Biomarkers be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →